New Company Focused on Candidates for CNS Diseases

A new pharma R&D player in the Central Nervous System (CNS) field, Accure Therapeutics, has launched with a Series A round of funding totalling €7.6 million ($8.1M) which was led by Alta Life Sciences and supported by the Centre for Technological and Industrial Development (CDTI). The company will develop new drug candidates to treat CNS diseases, supported by a seasoned team with solid pharma and biotech experience which will run operations.

The company is working on three distinct new medicine programs focused on innovative targets (POP, MMP, IGF1). The initial assets, ACT-01 ready for testing in a clinical phase 2 study and both ACT-02 and ACT-03 in preclinical experiments, have been sourced from Spanish R&D companies Bionure (1) and Iproteos (2) and academic research centres with a strong scientific background in neurobiology.

“With a portfolio that initially focuses on four CNS disorders – Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy – we are confident that Accure will create significant value in a CNS sector with significant market potential and pharma appetite for innovative new medicine programs,” said Montserrat Vendrell, partner at Alta Life Sciences. “Accure Therapeutics will operate according to the efficient small R&D pharma model and its team will be best positioned to deliver value to patients, care-givers, doctors and the industry at large.”

“We are proud to announce the launch of Accure Therapeutics,” said Laurent Nguyen, founding CEO of Accure Therapeutics. “The high quality assets in our product portfolio have the potential to change the lives of patients living with disabling CNS diseases. Life is a gift, let us work hard to respect it.”